参考文献/References:
[1] KOBAYASHI T, SIEGMUND B, LE BERRE C, et al. Ulcerative colitis[J]. Nature Reviews Disease Primers, 2020, 6(1): 74.[2] UNGARO R, MEHANDRU S, ALLEN P B, et al. Ulcerative colitis[J]. Lancet, 2016, 389(10080): 1756-1770.[3] SHAPIRO J M, ZOEGA H, SHAH S A, et al. Incidence of Crohn’s disease and ulcerative colitis in rhode island: Report from the ocean state Crohn’s and colitis area registry[J]. Inflammatory Bowel Diseases, 2016, 22(6): 1456-1461.[4] COSNES J, COWER-ROUSSEAU C, SEKSIK P, et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6): 1785-1794.[5] MOLODECKY N A, SOON I S, RABI D M, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1): 46-54.[6] LOFTUS C G, LOFTUS E V, HARMSEN W S, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000[J]. Inflammatory Bowel Diseases, 2007, 13(3): 254-261.[7] KUCHARZIK T, KOLETZKO S, KANNENGIEBER K, et al. Ulcerative colitis: Diagnostic and therapeutic algorithms[J]. Deutsches Aerzteblatt Online, 2020, 117: 33-34.[8] SALAS A, HERNANDEZ-ROCHA C, DUIJVESTEIN M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease[J]. Nature Reviews: Gastroenterology and Hepatology, 2020, 17(6): 323-337.[9] COSKUN M, SALEM M, PEDERSEN J, et al. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease[J]. Pharmacological Research, 2013, 76: 1-8.[10] O’SHEA J J, SCHWARTZ D M, VILLARINO A V, et al. The JAK-STAT pathway: Impact on human disease and therapeutic intervention[J]. Annual Review of Medicine, 2015, 66: 311-328.[11] WANG A, SINGH K, IBRAHIM W, et al. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature[J]. Yale Journal of Biology and Medicine, 2020, 93(1): 187-195.[12] KIM H O. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors[J]. Archives of Pharmacal Research, 2020, 43: 1173-1186.[13] XIN P, XU X Y, DENG C J, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. International Immunopharmacology, 2020, 80: 106210.[14] WANG X Q, LUPARDUS P, LAPORTE S L, et al. Structural biology of shared cytokine receptors[J]. Annual Review of Immunology, 2009, 27: 29-60.[15] ROCHMAN Y, SPOLSKI R, LEONARD W J. New insights into the regulation of T cells by gamma(c) family cytokines[J]. Nature Reviews Immunology, 2009, 9(7): 480-490.[16] YU H, PARDOLL D, JOVE R. STATs in cancer inflammation and immunity: A leading role for STAT3[J]. Nature Reviews Cancer, 2009, 9(11): 798-809.[17] BOENGLER K, HILFIKER-KLEINER D, DREXLER H, et al. The myocardial JAK/STAT pathway: From protection to failure[J]. Pharmacology and Therapeutics, 2008, 120(2): 172-185.[18] YAMAOKA K, SAHARINEN P, PESU M, et al. The Janus kinases (Jaks)[J]. Genome Biology, 2004, 5: 253.[19] ROBERTSON S A, KOLEVA R, ARGETSINGER L S, et al. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling[J]. Molecular and Cellular Biology, 2009, 29(12): 3367-3378.[20] LEVY D E, DAMELL J E. Stats: transcriptional control and biological impact[J]. Nature Reviews: Molecular Cell Biology, 2002, 3(9): 651-662.[21] 卢世文，余丽菲. JAK/STAT信号通路在小鼠心肌梗死发病中的作用及对NF-κB、TNF-α表达的影响[J]. 中国免疫学杂志，2022，38(5): 536-540.[22] KMIEC Z, CYMAN M, SLEBIODA T J. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease[J]. Advances in Medical Sciences, 2017, 62(1): 1-16.[23] SANCHEZ-MUNOZ F, DOMINGUEZ-LOPEZ A, YAMAMOTA-FURUSHO J K. Role of cytokines in inflammatory bowel disease[J]. World Journal of Gastroenterology, 2008, 27: 4280-4288.[24] SHUBHASREE B, ANN B, MASSIMO G, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects[J]. Drugs, 2017, 77: 521.[25] O’SHEA J J, KONTZIAS A, YAMAOKA K, et al. Janus kinase inhibitors in autoimmune diseases[J]. Annals of the Rheumatic Diseases, 2013, 72, Suppl 2(2): 111-115.[26] UNTERSMAYR E, BRANDT A, KOIDL L, et al. The Intestinal barrier dysfunction as driving factor of inflammaging[J]. Nutrients, 2022, 14(5): 949.[27] EHEHALT R, WAGENBLAST J, ERBEN G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients: A quantitative approach by nanoElectrospray-tandem mass spectrometry[J]. Scandinavian Journal of Gastroenterology, 2004, 39(8): 737-742.[28] SALIM S Y, SODERHOLM J D. Importance of disrupted intestinal barrier in inflammatory bowel diseases[J]. Inflammatory Bowel Diseases, 2011, 17(1): 362-381.[29] ORDAS I, ECKMANN L, TALAMINI M, et al. Ulcerative colitis[J]. Lancet, 2012, 380(9853): 1606-1619.[30] ]BLANCHARD C, DURUAL S, ESTIENNE M, et al. IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis[J]. Journal of Immunology, 2004, 172(6): 3775-3783.[31] LIU R X, MORIGGL R, ZHANG D S, et al. Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis[J]. Life Science Alliance, 2019, 2(2): e201900296.[32] CLAUDIA G, BARBARA R, IRIS S, et al. Interferon lambda promotes paneth cell death via STAT1 signaling in mice and is increased in inflamed ileal tissues of patients with Crohn’s disease[J]. Gastroenterology, 2019, 157(5): 1310-1322.[33] ZHOU X, LI W Y, WANG S, et al. YAP Aggravates inflammatory bowel disease by regulating M1/M2 macrophage polarization and gut microbial homeostasis[J]. Cell Reports, 2019, 27(4): 1176-1189.[34] ZHANG Y G, LI X Z, LUO Z G, et al. ECM1 is an essential factor for the determination of M1 macrophage polarization in IBD in response to LPS stimulation[J]. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117(6): 3083-3092.[35] NAJJAR I, FAGARD R. STAT1 and pathogens, not a friendly relationship[J]. Biochimie, 2010, 92(5): 425-444.[36] VIER J, GROTH M, SOCHALSKA M, et al. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling[J]. Cell Death and Disease, 2016, 7(2): e2103.[37] LI H Y S, YANG C Y, NALLAPARAJU K C, et al. The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development[J]. Blood, 2012, 120(22): 4363-4373.[38] YANG C, ZHANG Y, WANG J, et al. A novel cyclic helix B peptide inhibits dendritic cell maturation during amelioration of acute kidney graft rejection through Jak-2/STAT3/SOCS1[J]. Cell Death and Disease, 2015, 6: e1993.[39] 黄乐, 孙晓琳, 刘鹏飞. 溃疡性结肠炎组织中SOCS2、SOCS3表达量与炎症反应、免疫应答的相关性[J]. 海南医学院学报，2017，23(10): 1330-1333.[40] LAWRENCE T. The nuclear factor NF-kappaB pathway in inflammation[J]. Cold Spring Harbor Perspectives in Biology, 2009, 1(6): a001651.[41] CHEN L L, DENG H D, CUI H M, et al. Inflammatory responses and inflammation-associated diseases in organs[J]. Oncotarget, 2017, 9(6): 7204-7218. [42] ZUNDLER S, NEURATH M F. Integrating immunologic signaling networks: The JAK/STAT pathway in colitis and colitis-associated cancer[J]. Vaccines, 2016, 4(1): 5.[43] TANAKA T, NARAZALI M, KISHIMOTO T. IL-6 in inflammation, immunity, and disease[J]. Cold Spring Harbor Perspectives Biology, 2014, 6(10): a016295.[44] HEINRICH P C, MULLER-NEWEN G, SCHAPER F, et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway[J]. Biochemical Journal, 1998, 334( Pt 2): 297-314.[45] KAI Y, TAKAHASHI I, ISHIKAWA H, et al. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells[J]. Gastroenterology, 2005, 128(4): 922-934.[46] ATREYA R, MUDTER J, MULLBERG J, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo[J]. Nature Medicine, 2010, 16: 1341.[47] ATREYA R, NEURATH M F. Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer[J]. Current Drug Targets, 2008, 9(5): 369-374.[48] GRIVENNIKOV S, KARIN E, TERZIC J, et al. IL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer[J]. Cancer Cell, 2009, 15(2): 103-113.[49] NETO F C, MARTON L T, MARQUI S V D, et al. Curcuminoids from Curcuma Longa : New adjuvants for the treatment of crohn’s disease and ulcerative colitis[J]. Critical Reviews in Food Science and Nutrition, 2019, 59(13): 2136-2143.[50] ZHANG X X, WU J, YE B, et al. Protective effect of curcumin on TNBS-induced intestinal inflammation is mediated through the JAK/STAT pathway[J]. BMC Complementary Alternative Medcine, 2016, 16: 299.[51] NAKA T, NARAZAKI M, HIRATA M, et al. Structure and function of a new STAT-induced STAT inhibitor[J]. Nature, 1997, 387: 924-929.[52] 李阳，郝艺照，傅熠俊，等. 黄连素预防葡聚糖硫酸钠诱导溃疡性结肠炎的作用机制[J]. 中华中医药杂志，2017，32(8): 3431-3435.[53] 纪佳，陈岩岩. 黄芩汤对溃疡性结肠炎大鼠IL-6、JAK-STAT3信号通路及HMGB-1表达的影响[J]. 中医学报，2018，33(7): 1297-1301.[54] 沈洪，朱磊，刘亚军，等. 健脾补肾清肠方对溃疡性结肠炎模型大鼠结肠组织IL-6/JAK2/STAT3信号通路的影响[J]. 中医杂志，2020，61(22): 1977-1982.[55] WAN Y, ANG L, IANG S, et al. Excessive apoptosis in ulcerative colitis: Crosstalk between apoptosis, ROS, ER stress, and intestinal homeostasis[J]. Inflammatory Bowel Diseases, 2022, 28(4): 639-648.[56] PASPARAKIS M, VANDENABEELE P. Necroptosis and its role in inflammation[J]. Nature, 2015, 517: 311-320.[57] 步楠，王烨，王瑞，等. 雷公藤多苷通过JAK2/STAT3信号通路减轻溃疡性结肠炎大鼠肠黏膜细胞凋亡及炎症的实验研究[J]. 现代消化及介入诊疗，2019，24(5): 466-470.[58] 陈志涛，郑轶，杨静，等. 除湿健脾汤对溃疡性结肠炎小鼠IL-10/JAK1/STAT3通路及肠上皮细胞凋亡的影响[J]. 中医药导报，2021，27(5): 13-17.[59] 刘苗，申睿，朱向东，等. 痛泻要方对肝郁脾虚型溃疡性结肠炎模型大鼠TNF-α、Casepase3、Chop的影响[J]. 中医学报，2019，34(7): 1436-1441.